<span item_type="fundamental" item_id="345387f4366a154ea18ecf860679d068" counter_id="ST/US/FBIOP" env="prod"></span><span item_type="announcement" item_id="516465859661661697" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 13.14 M.</p><p>EPS: As of FY2025 Q1, the actual value is USD -0.48.</p><p></p><h3>Segment Revenue</h3><ul><li>Journey Medical’s net product revenues for the first quarter ended March 31, 2025, were $13.1 million, compared to $13.0 million for the first quarter ended March 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Consolidated research and development expenses totaled $3.9 million for the first quarter ended March 31, 2025, compared to $24.8 million for the first quarter ended March 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm"></span></li><li>Consolidated selling, general and administrative costs were $25.7 million for the first quarter ended March 31, 2025, compared to $17.9 million for the first quarter ended March 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm"></span></li><li>Consolidated net loss attributable to common stockholders was - $12.7 million, or - $0.48 per share, for the first quarter ended March 31, 2025, compared to - $17.9 million, or - $1.04 per share for the first quarter ended March 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>As of March 31, 2025, Fortress’ consolidated cash and cash equivalents totaled $91.3 million, compared to $57.3 million as of December 31, 2024, an increase of $34.0 million during the quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Fortress owns approximately 6.9 million shares of Checkpoint’s common stock and is eligible to receive a 2.5% royalty on future sales of UNLOXCYT.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Fortress is focused on key value drivers, including the September 30, 2025 PDUFA action date for CUTX-101, which may result in a Priority Review Voucher for Cyprium Therapeutics upon approval.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm"></span> The commercial launch of Emrosi is underway with initial prescriptions filled at the end of March.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm"></span> Fortress’ robust pipeline positions the company for continued revenue growth, value-driving milestones, and additional monetization opportunities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1429260/000155837025007878/fbio-20250515xex99.htm"></span></li></ul>

Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2025 Q1 Revenue: USD 13.14 M